
ESMO/LinkedIn
Jul 30, 2025, 14:46
Do OS, QoL and Pain Management Data Favour the Use of TTFields For the Treatment of LAPAC? – ESMO
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Quality of Life and Pain Management data from the PANOVA-3 trial adds to efficacy results of combining Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel as a potential new option of care for patients with locally advanced Pancreatic Adenocarcinoma (LAPAC).
Do Overall Survival, Quality of Life and pain management data taken together really favour the use of TTFields for the treatment of LAPAC?
Read the analysis by Angela Lamarca in the ESMO Daily Reporter to learn more about these results and their implications for patients.”
More posts featuring Tumor Treating Fields.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 30, 2025, 13:43
Jul 30, 2025, 13:30
Jul 30, 2025, 12:52
Jul 30, 2025, 11:57
Jul 30, 2025, 10:36
Jul 30, 2025, 10:32
Jul 30, 2025, 10:15